ARALAST Safety

• Considering Alpha-1 Testing
• Newly Diagnosed with Alpha-1
• Living With Alpha-1

ARALAST [Alpha₁-Proteinase Inhibitor (Human)] is prepared from human plasma using the Cohn-Oncley cold alcohol fractionation process.

ARALAST has a multi-step purification process that includes two viral treatment steps:

• Solvent Detergent Treatment rapidly inactivates lipid-enveloped viruses such as HIV and Hepatitis B and C.
• Nanofiltration reduces the risk of transmission of non-lipid-enveloped viral agents such as Hepatitis A and Parvovirus B19.

As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated.

ARALAST [Alpha₁-Proteinase Inhibitor (Human)] is indicated for chronic augmentation therapy in patients having congenital deficiency of A₁-PI with clinically evident emphysema. ARALAST is not indicated as therapy for lung disease patients in whom congenital A₁-PI deficiency has not been established.

Please review the Important Safety Information and the Full Prescribing Information